Search

Ibrutinib‐associated atrial fibrillation (IRAF) emerged among the adverse events of major interests in ibrutinib‐treated patients as real‐world studies showed a higher incidence compared to clinical trials. We prospectively analyzed predictors of IRAF in 43 single‐center consecutive patients affected by chronic lymphocytic leukemia that started therapy with ibrutinib between 2015 and 2017. Key secondary endpoints were to describe the management of IRAF and survival outcomes. During a median follow‐up period of 52 months, we registered 45 CV events, with a total of 23 AF events in 13 patients (CI 30.0% (95% CI: 16.5–43.9)). Pre‐existent cardiovascular risk factors, in particular hypertension, a previous history of AF and a high Shanafelt risk score emerged as predictors of IRAF. Baseline echocardiographic evaluation of left atrial (LA) dimensions confirmed to predict IRAF occurrence and cut‐off values were identified in our cohort: 32 mm for LA diameter and 18 cm2 for LA area. No difference in progression free survival and overall survival emerged in patients experiencing IRAF. Following AF, anticoagulation was started in all eligible patients, and cardioactive therapy was accordingly modified. Echocardiography represents a highly reproducible and widespread tool to be included in the work‐up of ibrutinib candidates; the identification of IRAF predictors represents a useful guide to clinical practice. [ABSTRACT FROM AUTHOR]

Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes: a second honeymoon? Median time from diagnosis to first rEPO was 3-4 months (0-87), median endogenous (e)EPO was 59 U/l (3-257) and 12 patients were transfusion dependent (median 4 units/8 weeks, range 2-7). Keywords: erythropoietin; myelodysplastic syndromes; transfusion EN erythropoietin myelodysplastic syndromes transfusion e147 e150 4 11/18/21 20211115 NES 211115 Duration of response to recombinant (r)EPO in myelodysplastic syndromes (MDS) is limited and further options are scanty, such that most subjects finally become transfusion dependent. [Extracted from the article]

Additionally, causes of secondary AA other than SARS-CoV-2 infection/vaccine should not be disregarded, including other infections, drugs, and the rarer congenital bone marrow failures. Keywords: aplastic anaemia; autoimmune haemolytic anaemia; immune thrombocytopenia; coronavirus disease 2019; severe acute respiratory syndrome coronavirus-2 vaccine EN aplastic anaemia autoimmune haemolytic anaemia immune thrombocytopenia coronavirus disease 2019 severe acute respiratory syndrome coronavirus-2 vaccine 1334 1336 3 03/22/22 20220315 NES 220315 There is increasing awareness about the possible relationship between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines and the development of haematological diseases, including autoimmune cytopenias (AICs) and complement-mediated diseases. Immune thrombocytopenia, severe acute respiratory syndrome coronavirus-2 vaccine, aplastic anaemia, autoimmune haemolytic anaemia, coronavirus disease 2019. [Extracted from the article]